‘Recurrent Vaginal Symptoms and Dysbiosis’
Understanding BV, Aerobic Vaginitis, Thrush and the Role of Lactobacilli in Vaginal Health

Abnormal vaginal discharge, odour, irritation and discomfort are among the most common reasons women seek healthcare advice. However, bacterial vaginosis (BV), aerobic vaginitis (AV) and vulvovaginal candidiasis (thrush) are distinct conditions with different underlying microbial drivers, often making accurate identification and long-term management challenging.

This webinar will explore the vaginal microbiome and the important role of Lactobacillus spp. in maintaining the vaginal environment. Attendees will gain a practical understanding of how changes in the vaginal microbiome can contribute to dysbiosis and recurrent symptoms, while exploring how BV, AV and thrush differ in their microbial drivers, presentation and aetiology.

The session will review current evidence surrounding microbiome restoration strategies, including the emerging role of targeted probiotic supplementation. Clinical evidence for specific, well-studied probiotic strains will be discussed including Lactobacillus rhamnosus GR-1® and Limosilactobacillus reuteri RC-14®, alongside practical considerations for supporting vaginal health, evidence relating to recurrence, and the use of microbiome-focused approaches alongside conventional management.

By the end of the session, delegates will have a greater understanding of the relationship between the vaginal microbiome and recurrent vaginal symptoms, enabling them to make more informed, evidence-based recommendations in clinical practice.

Learning Objectives

By the end of this webinar, delegates will be able to:

• Differentiate the key clinical and microbial characteristics of bacterial vaginosis, aerobic vaginitis and vulvovaginal candidiasis.
• Understand the role of Lactobacillus spp. and vaginal microbial ecology in maintaining vaginal health.
• Recognise how different patterns of vaginal dysbiosis may contribute to recurrent vaginal symptoms.
• Evaluate current evidence for targeted probiotic interventions in vaginal health.
• Apply microbiome-focused strategies alongside conventional approaches to support women experiencing recurrent vaginal symptoms.

‘Beyond “Detox”: Using Pharmacogenetics to Understand Drug Activation, Clearance and Biotransformation’

Detoxification is frequently discussed as a generalised process of “removing toxins”, yet clinically it represents a coordinated system of Phase I biotransformation, antioxidant protection and Phase II conjugation that also determines how many medications are activated, metabolised and eliminated.

This presentation uses an anonymised female case study to demonstrate how genetic data can provide additional context for individual variation in drug response.

The profile identifies potentially reduced CYP2D6 activity, with implications for reduced activation of prodrugs such as codeine and tramadol, while medications dependent on CYP2D6 for clearance may instead achieve higher exposure.

A CYP2C19 intermediate metaboliser profile provides a contrasting example, where reduced enzyme activity may decrease activation of clopidogrel while slowing clearance of medications including proton pump inhibitors, selected antidepressants and diazepam – particularly important with a family history of depression.

The case also explores how Phase I metabolism must be considered alongside downstream metabolic capacity.

Variants affecting SULT1A1 sulphation, GSTM1 glutathione conjugation and UGT1A6 glucuronidation illustrate how reactive intermediates and drug metabolites ultimately require effective antioxidant buffering and Phase II elimination.
Rather than using genotype to dictate prescribing, the presentation proposes a pathway based approach integrating pharmacogenetics with medication history, drug-drug and drug-nutrient interactions, clinical response and appropriate monitoring.

The aim is to demonstrate how genetic information can help explain unexpected efficacy or adverse effects of prescription medication while supporting safer, more individualised medication use.

‘Mould & the Cell: Building Resilience from the Inside Out’

Mould exposure is often approached through avoidance and detoxification, but understanding the cellular response to environmental stressors adds an important layer to the clinical picture. In this webinar, Dr. John Kim, Pharm.D., FAARFM, will explore mould through a cellular health lens, connecting environmental exposures with mitochondrial function, cell membrane health, redox balance, nervous system regulation, gut health, and endogenous detoxification pathways. He will discuss strategies designed to support normal cellular function and resilience, with an emphasis on building physiological capacity and supporting the cellular foundations that help the body adapt, regulate, and restore balance.